{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:30:34Z","timestamp":1785007834198,"version":"3.55.0"},"reference-count":16,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Res Paediatr"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>Background\/Aims: Hypoparathyroidism associated with malabsorption can be particularly challenging to manage due to limited and erratic intestinal absorption of calcium and vitamin D analogues, resulting in episodes of hypo- or hypercalcaemia. We evaluated the role of continuous subcutaneous recombinant parathyroid hormone (rhPTH 1\u201334) infusion (CSPI) in children with hypoparathyroidism associated with intestinal malabsorption resistant to conventional therapy. Method: Four patients (8\u201313 years of age), with symptomatic hypocalcaemia resistant to conventional therapy, were started on CSPI (follow-up 3\u20138 years) in two paediatric endocrinology units in Europe. Results: Serum calcium normalized within 48 h of commencing treatment in all 4 patients. An average rhPTH 1\u201334 dose of 0.4 \u00b5g\/kg\/day resulted in a substantial reduction in symptomatic hypocalcaemia and hypo-\/hypercalcaemia-related hospital admissions. An increased alkaline phosphatase activity was noted in the first 6 months on CSPI, indicating an increase in bone turnover. In 2 patients with elevated urinary calcium excretion before CSPI, this normalized in the first year on treatment. No significant side effects were noticed in the short or long term, with patient-reported preference of CSPI over conventional treatment. Conclusion: CSPI is a promising and effective treatment option for managing hypocalcaemia and hyperphosphataemia in children with hypoparathyroidism associated with intestinal malabsorption.<\/jats:p>","DOI":"10.1159\/000479867","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T21:02:08Z","timestamp":1505854928000},"page":"271-277","source":"Crossref","is-referenced-by-count":26,"title":["Continuous Subcutaneous Recombinant Parathyroid Hormone (1\u201334) Infusion in the Management of Childhood Hypoparathyroidism Associated with Malabsorption"],"prefix":"10.1159","volume":"89","author":[{"given":"Vrinda","family":"Saraff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Rothenbuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6304","authenticated-orcid":false,"given":"Wolfgang","family":"H\u00f6gler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1023\/B:REMD.0000016123.21743.fe"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1029"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0803050"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(85)80668-5"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540080053029"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021736"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2552"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.04.060"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1359"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/01926230490462138"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/01926230252929882"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080807"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1586\/17446651.2015.971755"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.452"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2014.01.003"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070716"}],"container-title":["Hormone Research in Paediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/hrp\/article-pdf\/89\/4\/271\/3896222\/000479867.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/hrp\/article-pdf\/89\/4\/271\/3896222\/000479867.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:50:03Z","timestamp":1745427003000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000479867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,6,7]]},"published-print":{"date-parts":[[2018,6,15]]}},"URL":"https:\/\/doi.org\/10.1159\/000479867","archive":["Portico"],"relation":{},"ISSN":["1663-2818","1663-2826"],"issn-type":[{"value":"1663-2818","type":"print"},{"value":"1663-2826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,19]]}}}